Literature DB >> 1601969

Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.

O van Tellingen1, A Kuijpers, J H Beijnen, M R Baselier, J T Burghouts, W J Nooyen.   

Abstract

A simple and selective procedure for the determination of vinorelbine, a new semi-synthetic vinca alkaloid, is presented. The method is based on ion-exchange high-performance liquid chromatography on normal-phase silica with fluorescence detection, combined with liquid-liquid extraction using diethyl ether for sample clean-up. The absence of endogenous interferences and the excellent chromatographic behaviour of vinca alkaloids provides accurate results even at low concentrations. The limit of determination in plasma is 1.5 micrograms/l (500-microliters sample). Reproducible recoveries in urine were obtained if 10-50 microliters of sample were processed supplemented with 500 microliters of blank plasma.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1601969     DOI: 10.1016/0378-4347(92)80138-g

Source DB:  PubMed          Journal:  J Chromatogr


  5 in total

Review 1.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 2.  Bioanalysis and pharmacokinetics of (investigational) vinca alkaloids.

Authors:  O van Tellingen
Journal:  Pharm World Sci       Date:  1994-06-10

Review 3.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

4.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

5.  A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine.

Authors:  Jame Abraham; Maureen Edgerly; Richard Wilson; Clara Chen; Ann Rutt; Susan Bakke; Rob Robey; Andrew Dwyer; Barry Goldspiel; Frank Balis; Olaf Van Tellingen; Susan E Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.